CD200在肾细胞癌中的免疫组化表达

Immunohistochemical Expression of CD200 in Renal Cell Carcinoma.

作者信息

El Hanbuli Hala M, Ibrahim Heba A, Soliman Somia A M

机构信息

Department of Pathology, Faculty of Medicine, Fayoum University, Faiyum, Egypt.

Department of Pathology, Faculty of Medicine, Cairo University, Giza, Egypt.

出版信息

J Microsc Ultrastruct. 2020 Dec 29;9(3):136-140. doi: 10.4103/JMAU.JMAU_29_20. eCollection 2021 Jul-Sep.

DOI:10.4103/JMAU.JMAU_29_20

PMID:34729355

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8507520/

Abstract

BACKGROUND AND OBJECTIVES

Renal cell carcinoma (RCC) is the most common malignant renal neoplasm in adults. CD200 is a transmembrane protein and is a promising target for cancer immunotherapy. The aim of this study is to assess the CD200 expression in RCC.

MATERIALS AND METHODS

Eighty paraffin-embedded radical nephrectomy specimens, diagnosed with RCC were evaluated immunohistochemically for CD200 expression.

RESULTS

Out of eighty cases studied, CD200 was expressed in = 73 cases (91.25%) with high intensity in 27 cases (33.75%), moderate intensity in 22 cases (27.5%), and mild intensity in 24 cases (30%). No staining was observed in the adjacent apparently normal renal tissue in all examined sections. No significant relationship was found between CD200 expression and the gender, tumor size, tumor side, histologic type, nuclear grade, T stage, and tumor necrosis.

CONCLUSION

CD200 expression in most of the studied cases of RCC may refer to the potential therapeutic of anti-CD200 antibody for this cancer.

摘要

背景与目的

肾细胞癌（RCC）是成人中最常见的恶性肾肿瘤。CD200是一种跨膜蛋白，是癌症免疫治疗的一个有前景的靶点。本研究的目的是评估CD200在肾细胞癌中的表达。

材料与方法

对80例经诊断为肾细胞癌的石蜡包埋根治性肾切除术标本进行免疫组织化学评估，以检测CD200的表达。

结果

在研究的80例病例中，73例（91.25%）表达CD200，其中27例（33.75%）为高强度表达，22例（27.5%）为中等强度表达，24例（30%）为低强度表达。在所有检查切片中，相邻的明显正常肾组织均未观察到染色。CD200表达与性别、肿瘤大小、肿瘤侧别、组织学类型、核分级、T分期和肿瘤坏死之间均未发现显著相关性。